Cargando…

Syndecan-1 Predicts Outcome in Patients with ST-Segment Elevation Infarction Independent from Infarct-related Myocardial Injury

Syndecan-1 (sdc1) is a surface protein part of the endothelial glycocalyx (eGC). Soluble sdc1 is derived from shedding and indicates damaged eGC. We assessed the predictive value of plasma sdc1 concentrations for future cardiovascular events in acute reperfused ST-segment elevation myocardial infarc...

Descripción completa

Detalles Bibliográficos
Autores principales: Wernly, Bernhard, Fuernau, Georg, Masyuk, Maryna, Muessig, Johanna Maria, Pfeiler, Susanne, Bruno, Raphael Romano, Desch, Steffen, Muench, Phillip, Lichtenauer, Michael, Kelm, Malte, Adams, Volker, Thiele, Holger, Eitel, Ingo, Jung, Christian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6892872/
https://www.ncbi.nlm.nih.gov/pubmed/31797997
http://dx.doi.org/10.1038/s41598-019-54937-x
_version_ 1783476100564779008
author Wernly, Bernhard
Fuernau, Georg
Masyuk, Maryna
Muessig, Johanna Maria
Pfeiler, Susanne
Bruno, Raphael Romano
Desch, Steffen
Muench, Phillip
Lichtenauer, Michael
Kelm, Malte
Adams, Volker
Thiele, Holger
Eitel, Ingo
Jung, Christian
author_facet Wernly, Bernhard
Fuernau, Georg
Masyuk, Maryna
Muessig, Johanna Maria
Pfeiler, Susanne
Bruno, Raphael Romano
Desch, Steffen
Muench, Phillip
Lichtenauer, Michael
Kelm, Malte
Adams, Volker
Thiele, Holger
Eitel, Ingo
Jung, Christian
author_sort Wernly, Bernhard
collection PubMed
description Syndecan-1 (sdc1) is a surface protein part of the endothelial glycocalyx (eGC). Soluble sdc1 is derived from shedding and indicates damaged eGC. We assessed the predictive value of plasma sdc1 concentrations for future cardiovascular events in acute reperfused ST-segment elevation myocardial infarction (STEMI) patients. A total of 206 patients admitted for STEMI were included in this study (29% female; age 65 ± 12 years) and followed-up for six months. Plasma samples were obtained post-intervention and analyzed for sdc1 by Enzyme-linked Immunosorbent Assay (ELISA). Primary outcome was six-month-mortality. Sdc1 did not correlate with biomarkers such as creatine kinase (CK) (r = 0.11; p = 0.01) or troponin (r = −0.12; p = 0.09), nor with infarct size (r = −0.04; p = 0.67) and myocardial salvage index (r = 0.11; p = 0.17). Sdc-1 was associated with mortality (changes per 100 ng/mL sdc-1 concentration; HR 1.08 95% 1.03–1.12; p = 0.001). An optimal cut-off was calculated at >120 ng/mL. After correction for known risk factors sdc1 >120 ng/mL was independently associated with mortality after 6 months. In our study, sdc1 is independently associated with six-month-mortality after STEMI. Combining clinical evaluation and different biomarkers assessing both infarct-related myocardial injury and systemic stress response might improve the accuracy of predicting clinical prognosis in STEMI patients.
format Online
Article
Text
id pubmed-6892872
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-68928722019-12-11 Syndecan-1 Predicts Outcome in Patients with ST-Segment Elevation Infarction Independent from Infarct-related Myocardial Injury Wernly, Bernhard Fuernau, Georg Masyuk, Maryna Muessig, Johanna Maria Pfeiler, Susanne Bruno, Raphael Romano Desch, Steffen Muench, Phillip Lichtenauer, Michael Kelm, Malte Adams, Volker Thiele, Holger Eitel, Ingo Jung, Christian Sci Rep Article Syndecan-1 (sdc1) is a surface protein part of the endothelial glycocalyx (eGC). Soluble sdc1 is derived from shedding and indicates damaged eGC. We assessed the predictive value of plasma sdc1 concentrations for future cardiovascular events in acute reperfused ST-segment elevation myocardial infarction (STEMI) patients. A total of 206 patients admitted for STEMI were included in this study (29% female; age 65 ± 12 years) and followed-up for six months. Plasma samples were obtained post-intervention and analyzed for sdc1 by Enzyme-linked Immunosorbent Assay (ELISA). Primary outcome was six-month-mortality. Sdc1 did not correlate with biomarkers such as creatine kinase (CK) (r = 0.11; p = 0.01) or troponin (r = −0.12; p = 0.09), nor with infarct size (r = −0.04; p = 0.67) and myocardial salvage index (r = 0.11; p = 0.17). Sdc-1 was associated with mortality (changes per 100 ng/mL sdc-1 concentration; HR 1.08 95% 1.03–1.12; p = 0.001). An optimal cut-off was calculated at >120 ng/mL. After correction for known risk factors sdc1 >120 ng/mL was independently associated with mortality after 6 months. In our study, sdc1 is independently associated with six-month-mortality after STEMI. Combining clinical evaluation and different biomarkers assessing both infarct-related myocardial injury and systemic stress response might improve the accuracy of predicting clinical prognosis in STEMI patients. Nature Publishing Group UK 2019-12-04 /pmc/articles/PMC6892872/ /pubmed/31797997 http://dx.doi.org/10.1038/s41598-019-54937-x Text en © The Author(s) 2019 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
spellingShingle Article
Wernly, Bernhard
Fuernau, Georg
Masyuk, Maryna
Muessig, Johanna Maria
Pfeiler, Susanne
Bruno, Raphael Romano
Desch, Steffen
Muench, Phillip
Lichtenauer, Michael
Kelm, Malte
Adams, Volker
Thiele, Holger
Eitel, Ingo
Jung, Christian
Syndecan-1 Predicts Outcome in Patients with ST-Segment Elevation Infarction Independent from Infarct-related Myocardial Injury
title Syndecan-1 Predicts Outcome in Patients with ST-Segment Elevation Infarction Independent from Infarct-related Myocardial Injury
title_full Syndecan-1 Predicts Outcome in Patients with ST-Segment Elevation Infarction Independent from Infarct-related Myocardial Injury
title_fullStr Syndecan-1 Predicts Outcome in Patients with ST-Segment Elevation Infarction Independent from Infarct-related Myocardial Injury
title_full_unstemmed Syndecan-1 Predicts Outcome in Patients with ST-Segment Elevation Infarction Independent from Infarct-related Myocardial Injury
title_short Syndecan-1 Predicts Outcome in Patients with ST-Segment Elevation Infarction Independent from Infarct-related Myocardial Injury
title_sort syndecan-1 predicts outcome in patients with st-segment elevation infarction independent from infarct-related myocardial injury
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6892872/
https://www.ncbi.nlm.nih.gov/pubmed/31797997
http://dx.doi.org/10.1038/s41598-019-54937-x
work_keys_str_mv AT wernlybernhard syndecan1predictsoutcomeinpatientswithstsegmentelevationinfarctionindependentfrominfarctrelatedmyocardialinjury
AT fuernaugeorg syndecan1predictsoutcomeinpatientswithstsegmentelevationinfarctionindependentfrominfarctrelatedmyocardialinjury
AT masyukmaryna syndecan1predictsoutcomeinpatientswithstsegmentelevationinfarctionindependentfrominfarctrelatedmyocardialinjury
AT muessigjohannamaria syndecan1predictsoutcomeinpatientswithstsegmentelevationinfarctionindependentfrominfarctrelatedmyocardialinjury
AT pfeilersusanne syndecan1predictsoutcomeinpatientswithstsegmentelevationinfarctionindependentfrominfarctrelatedmyocardialinjury
AT brunoraphaelromano syndecan1predictsoutcomeinpatientswithstsegmentelevationinfarctionindependentfrominfarctrelatedmyocardialinjury
AT deschsteffen syndecan1predictsoutcomeinpatientswithstsegmentelevationinfarctionindependentfrominfarctrelatedmyocardialinjury
AT muenchphillip syndecan1predictsoutcomeinpatientswithstsegmentelevationinfarctionindependentfrominfarctrelatedmyocardialinjury
AT lichtenauermichael syndecan1predictsoutcomeinpatientswithstsegmentelevationinfarctionindependentfrominfarctrelatedmyocardialinjury
AT kelmmalte syndecan1predictsoutcomeinpatientswithstsegmentelevationinfarctionindependentfrominfarctrelatedmyocardialinjury
AT adamsvolker syndecan1predictsoutcomeinpatientswithstsegmentelevationinfarctionindependentfrominfarctrelatedmyocardialinjury
AT thieleholger syndecan1predictsoutcomeinpatientswithstsegmentelevationinfarctionindependentfrominfarctrelatedmyocardialinjury
AT eitelingo syndecan1predictsoutcomeinpatientswithstsegmentelevationinfarctionindependentfrominfarctrelatedmyocardialinjury
AT jungchristian syndecan1predictsoutcomeinpatientswithstsegmentelevationinfarctionindependentfrominfarctrelatedmyocardialinjury